A detailed history of Bio Impact Capital LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 2,406,714 shares of IOVA stock, worth $18.8 Million. This represents 3.53% of its overall portfolio holdings.

Number of Shares
2,406,714
Previous 2,366,714 1.69%
Holding current value
$18.8 Million
Previous $19 Million 19.06%
% of portfolio
3.53%
Previous 3.05%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$7.28 - $11.9 $291,200 - $476,000
40,000 Added 1.69%
2,406,714 $22.6 Million
Q2 2024

Aug 14, 2024

BUY
$7.78 - $14.19 $1.3 Million - $2.37 Million
166,714 Added 7.58%
2,366,714 $19 Million
Q1 2024

May 15, 2024

SELL
$7.59 - $17.47 $8.27 Million - $19 Million
-1,089,470 Reduced 33.12%
2,200,000 $32.6 Million
Q4 2023

Feb 13, 2024

BUY
$3.3 - $8.89 $1.12 Million - $3.02 Million
339,352 Added 11.5%
3,289,470 $26.7 Million
Q2 2023

Aug 14, 2023

BUY
$5.36 - $9.06 $1.8 Million - $3.04 Million
335,141 Added 12.82%
2,950,118 $20.8 Million
Q1 2023

May 12, 2023

BUY
$5.53 - $8.22 $2.57 Million - $3.83 Million
465,427 Added 21.65%
2,614,977 $16 Million
Q4 2022

Feb 14, 2023

BUY
$5.62 - $10.0 $2.53 Million - $4.5 Million
449,550 Added 26.44%
2,149,550 $13.7 Million
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $4.77 Million - $6.56 Million
500,000 Added 41.67%
1,700,000 $16.3 Million
Q2 2022

Aug 11, 2022

BUY
$6.38 - $18.33 $7.66 Million - $22 Million
1,200,000 New
1,200,000 $13.2 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.23B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Bio Impact Capital LLC Portfolio

Follow Bio Impact Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bio Impact Capital LLC with notifications on news.